Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivastigmine
Drug ID BADD_D01955
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D03822
MeSH ID D000068836
PubChem ID 77991
TTD Drug ID D0WY5Q
NDC Product Code 0378-9071; 51956-0001; 51956-0003; 70710-1198; 65162-826; 49706-1825; 51956-0002; 0078-0502; 72855-100; 0378-9070; 50379-0014; 65015-819; 46708-835; 51991-899; 0078-0503; 63629-8846; 65862-982; 65162-825; 72855-101; 63629-8807; 63629-2065; 65162-749; 51991-898; 0378-9072; 64552-4021; 0781-7313; 72855-102; 16714-117; 16714-116; 51991-897; 0781-7309; 70710-1196; 12651-118; 63629-2066; 0078-0501; 16714-115; 0781-7304; 65372-1153; 82245-0107; 63629-2064; 70710-1197
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C14H22N2O2
CAS Registry Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AstheniaCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
DiarrhoeaCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
DizzinessCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
VomitingCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Syncope24.06.02.012; 02.01.02.008; 17.02.04.0080.011178%
Tachycardia02.03.02.007--Not Available
Tachypnoea22.02.01.0140.003726%Not Available
Thinking abnormal17.02.05.023; 19.10.03.0010.004968%Not Available
Tremor17.01.06.0020.007452%
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.003726%
Vertigo17.02.12.002; 04.04.01.0030.008694%
Vomiting07.01.07.0030.027324%
Weight decreased13.15.01.0050.006210%
Mobility decreased17.02.05.018; 15.03.01.003; 08.01.03.0300.002484%Not Available
Bradyarrhythmia02.03.02.0150.003726%Not Available
Musculoskeletal stiffness15.03.01.0050.004968%Not Available
Cognitive disorder17.03.03.003; 19.21.02.0010.006210%
Freezing phenomenon17.01.05.0060.003726%Not Available
Mental disorder19.07.01.0020.002484%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.003726%
Parkinson's disease17.01.05.0100.000972%Not Available
Drug intolerance08.06.01.0130.002484%Not Available
Psychotic disorder19.03.01.0020.003726%
Application site hypersensitivity08.02.01.013; 12.07.01.014; 10.01.03.009--Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.003726%Not Available
Acute kidney injury20.01.03.0160.004968%
Medication residue present13.15.01.0320.002484%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000972%
The 4th Page    First    Pre   4    Total 4 Pages